News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
715,724 Results
Type
Article (42375)
Company Profile (294)
Press Release (673055)
Section
Business (210411)
Career Advice (2093)
Deals (36629)
Drug Delivery (106)
Drug Development (83020)
Employer Resources (175)
FDA (16551)
Job Trends (15403)
News (355962)
Policy (33885)
Tag
2024 BioCapital Digital (12)
2024 BioForest Digital (4)
2024 BioForest Standard (1)
2024 BioMidwest Digital (9)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (7)
2024 Bio NC Standard (2)
2024 Biotech Bay Standard (18)
2024 Biotech Beach Digital (9)
2024 Biotech Beach Standard (5)
2024 Genetown Digital (8)
2024 Genetown Standard (11)
2024 Lone Star Bio Digital (5)
2024 Pharm Country Digital (6)
2024 Pharm Country Standard (6)
2025 BioForest Digital (3)
2025 Lone Star Bio Digital (6)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Pharm Country Standard (1)
Academia (2595)
Accelerated approval (2)
Adcomms (21)
Allergies (84)
Alliances (51373)
ALS (85)
Alzheimer's disease (1364)
Antibody-drug conjugate (ADC) (115)
Approvals (16552)
Artificial intelligence (242)
Autoimmune disease (15)
Automation (14)
Bankruptcy (371)
Best Places to Work (11776)
BIOSECURE Act (19)
Biosimilars (107)
Biotechnology (188)
Bladder cancer (56)
Brain cancer (26)
Breast cancer (248)
Cancer (2004)
Cardiovascular disease (163)
Career advice (1751)
Career pathing (30)
CAR-T (141)
Cell therapy (398)
Cervical cancer (18)
Clinical research (67222)
Collaboration (781)
Compensation (451)
Complete response letters (25)
COVID-19 (2652)
CRISPR (40)
C-suite (209)
Cystic fibrosis (101)
Data (1930)
Decentralized trials (2)
Denatured (26)
Depression (39)
Diabetes (251)
Diagnostics (6415)
Digital health (17)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (113)
Drug pricing (107)
Drug shortages (28)
Duchenne muscular dystrophy (85)
Earnings (87838)
Editorial (33)
Employer branding (21)
Employer resources (149)
Events (114501)
Executive appointments (642)
FDA (17667)
Featured Employer (50)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (693)
Gene editing (101)
Generative AI (20)
Gene therapy (289)
GLP-1 (718)
Government (4499)
Grass and pollen (4)
Guidances (48)
Healthcare (18998)
Huntington's disease (23)
IgA nephropathy (22)
Immunology and inflammation (112)
Indications (27)
Infectious disease (2781)
Inflammatory bowel disease (135)
Inflation Reduction Act (8)
Influenza (46)
Intellectual property (85)
Interviews (322)
IPO (16763)
IRA (47)
Job creations (4057)
Job search strategy (1494)
Kidney cancer (9)
Labor market (34)
Layoffs (471)
Leadership (16)
Legal (8367)
Liver cancer (71)
Lung cancer (291)
Lymphoma (131)
Machine learning (2)
Management (59)
Manufacturing (277)
MASH (62)
Medical device (13405)
Medtech (13410)
Mergers & acquisitions (20327)
Metabolic disorders (650)
Multiple sclerosis (68)
NASH (17)
Neurodegenerative disease (80)
Neuropsychiatric disorders (26)
Neuroscience (1844)
NextGen: Class of 2025 (6641)
Non-profit (4526)
Northern California (2405)
Now hiring (37)
Obesity (353)
Opinion (226)
Ovarian cancer (73)
Pain (85)
Pancreatic cancer (77)
Parkinson's disease (131)
Partnered (20)
Patents (206)
Patient recruitment (94)
Peanut (49)
People (59049)
Pharmaceutical (91)
Pharmacy benefit managers (19)
Phase I (20844)
Phase II (29577)
Phase III (22174)
Pipeline (983)
Podcasts (74)
Policy (120)
Postmarket research (2654)
Preclinical (8835)
Press Release (68)
Prostate cancer (93)
Psychedelics (31)
Radiopharmaceuticals (249)
Rare diseases (369)
Real estate (6254)
Recruiting (67)
Regulatory (22986)
Reports (46)
Research institute (2367)
Resumes & cover letters (358)
Rett syndrome (3)
RNA editing (3)
RSV (37)
Schizophrenia (70)
Series A (123)
Series B (78)
Service/supplier (12)
Sickle cell disease (52)
Southern California (2077)
Special edition (15)
Spinal muscular atrophy (150)
Sponsored (29)
Startups (3722)
State (2)
Stomach cancer (14)
Supply chain (60)
The Weekly (45)
United States (21129)
Vaccines (673)
Venture capitalists (37)
Webinars (12)
Weight loss (241)
Women's health (33)
Worklife (15)
Date
Today (113)
Last 7 days (621)
Last 30 days (2547)
Last 365 days (34103)
2025 (7870)
2024 (35772)
2023 (40631)
2022 (51803)
2021 (56336)
2020 (54800)
2019 (47423)
2018 (35790)
2017 (33138)
2016 (32683)
2015 (38631)
2014 (32523)
2013 (27639)
2012 (29740)
2011 (30493)
2010 (28500)
Location
Africa (782)
Alabama (49)
Alaska (7)
Arizona (230)
Arkansas (14)
Asia (40592)
Australia (6499)
California (5489)
Canada (1868)
China (480)
Colorado (247)
Connecticut (257)
Delaware (127)
Europe (86520)
Florida (813)
Georgia (190)
Idaho (57)
Illinois (502)
India (24)
Indiana (298)
Iowa (9)
Japan (144)
Kansas (100)
Kentucky (23)
Louisiana (7)
Maine (60)
Maryland (833)
Massachusetts (4163)
Michigan (211)
Minnesota (368)
Mississippi (2)
Missouri (75)
Montana (27)
Nebraska (25)
Nevada (56)
New Hampshire (62)
New Jersey (1572)
New Mexico (29)
New York (1571)
North Carolina (931)
North Dakota (7)
Northern California (2405)
Ohio (190)
Oklahoma (14)
Oregon (38)
Pennsylvania (1251)
Puerto Rico (9)
Rhode Island (26)
South America (1161)
South Carolina (18)
South Dakota (1)
Southern California (2077)
Tennessee (92)
Texas (823)
Utah (165)
Virginia (135)
Washington D.C. (57)
Washington State (515)
West Virginia (3)
Wisconsin (51)
715,724 Results for "elite pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Policy
Elite Pharmaceuticals Receives FDA Approval for Generic Methotrexate
Elite Pharmaceuticals, Inc. announced that it received approval from the US Food and Drug Administration for an Abbreviated New Drug Application for generic Methotrexate Sodium 2.5 mg tablets.
May 20, 2024
·
2 min read
Business
Elite Pharmaceuticals, Inc. Reports Financial Results for Third Quarter of Fiscal Year 2024 ended December 31, 2023 and Provides Conference Call Information
Elite Pharmaceuticals, Inc. announced results for the third quarter of fiscal year 2024 ended December 31, 2023.
February 14, 2024
·
3 min read
Pharm Country
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2024 Financial Results on February 15, 2024
Elite Pharmaceuticals, Inc. announced today that the third quarter financial results of the 2024 fiscal year will be released on Wednesday, February 14, 2024.
February 8, 2024
·
2 min read
Business
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2024 Financial Results on November 15, 2023
Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCBB:ELTP), a specialty pharmaceutical company developing niche generic products, announced today that the second quarter financial results of the 2024 fiscal year will be released on Tuesday, November 14, 2023.
November 10, 2023
·
2 min read
Business
Elite Pharmaceuticals, Inc. Appoints Carter Ward as Chief Financial Officer
Elite Pharmaceuticals, Inc., a specialty pharmaceutical company developing and manufacturing niche generic products, announced the appointment of Carter Ward as its Chief Financial Officer, effective September 5, 2023.
September 7, 2023
·
3 min read
Business
Elite Pharmaceuticals, Inc. Reports Financial Results for Second Quarter of Fiscal Year 2024 ended September 30, 2023 and Provides Conference Call Information
Elite Pharmaceuticals, Inc., a specialty pharmaceutical company engaged in the development, manufacture, and distribution of niche generic products, announced results for the second quarter of fiscal year 2024 ended September 30, 2023.
November 14, 2023
·
3 min read
Policy
Elite Pharmaceuticals Files ANDA with US FDA to Market Central Nervous System Stimulant
Elite Pharmaceuticals, Inc. announced the US Food and Drug Administration’s acceptance for review of an Abbreviated New Drug Application on December 21, 2023, for an undisclosed generic drug product in a class of medications known as central nervous stimulants.
December 26, 2023
·
2 min read
Pharm Country
Elite Pharmaceuticals Announces First Product Shipment of Generic Adderall XR(R) to Marketing Partner Prasco, LLC
Elite Pharmaceuticals, Inc. today announced the first shipment of generic Adderall XR to its distribution and marketing partner Prasco, LLC.
December 12, 2023
·
2 min read
Business
Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2023 and Provides Conference Call Information
Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, announced results for the fiscal year ended March 31, 2023 (“Fiscal 2023").
June 29, 2023
·
3 min read
Business
Elite Pharmaceuticals, Inc. Appoints Mark Pellegrino as Chief Financial Officer
Elite Pharmaceuticals, Inc., a specialty pharmaceutical company developing and manufacturing niche generic products, announced the appointment of Mark Pellegrino as its Chief Financial Officer, effective May 1, 2023.
May 3, 2023
·
2 min read
1 of 71,573
Next
